You're invited to join an exciting new webinar by our Head of Assay Development Dr Marta Veses Garcia on 18th of June at 14.00 CEST.
(STOCKHOLM) Symcel — a company providing continuous metabolic measurements of living organisms — today announced a new rights issue worth 86 MSEK, financed by a consortium of private health and technology investors including Lareim AB and Flerie...
The 6th Annual MarketsandMarkets Next-Gen Microbiome and Probiotics Conference, set to convene on the West Coast, presents a great opportunity for Symcel. Here, the brightest minds and the latest advancements in microbiome and probiotics research...
In a recent publication in the Journal of Clinical Microbiology, a team of orthopedic surgeons compared the calScreener™ to traditional detection methods and found that it was possible to identify prosthetic joint infections from intraoperative...
[STOCKHOLM, OCTOBER 2023] - Symcel, a leading medtech company transforming rapid infection diagnostics and microbial testing, is thrilled to announce the appointment of Pia van der Zee as its new Chief Commercial Officer (CCO). This strategic move...
We are thrilled to announce that Symcel has been awarded a grant to further develop fast diagnostics for prosthesis and joint infections. This exciting development represents a major step forward in our ongoing efforts to improve patient outcomes...
This week we are happy to welcome a brand new addition to the Symcel family, Kasper Kragh.
- This shift in metabolism has strong implications for tolerance to antibiotics
Today our Principal Scientist, Dr. Marta Veses Garcia will present at the United States Pharmacopeia event.
- The move brings Symcel closer to one of the world's biggest life science hubs